Justin L. Ricker - Concepedia

Author

Justin L. Ricker

The University of Texas MD Anderson Cancer Center

Also Known As

J RICKER, J. L. Ricker, J. Ricker, J.L. Ricker, JUSTIN L. RICKER, Justin L. Ricker, Justin Ricker

Publications

6.6K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center AbbVie (United States)Merck & Co., Inc., Rahway, NJ, USA (United States)Dana-Farber Cancer Institute Abbott Fund

About

Justin L. Ricker is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	20	1.1K
2	Health Sciences	5	5	147
3	Biostatistics	1	1	18
4	Cell Biology	1	1	13
5	Diagnostic Sciences	1	1	20

Justin L. Ricker

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Madeleine Duvic, Rakshandra Talpur, Xiao Ni, Blood	2006	1.1K
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri, Cancer Discovery	2016	1K
Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma Elise A. Olsen, Youn H. Kim, Timothy M. Kuzel, Journal of Clinical Oncology	2007	1K
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial Călin Cainap, Shukui Qin, Wen‐Tsung Huang, Journal of Clinical Oncology	2014	623
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes Guillermo Garcia‐Manero, Hui Yang, Carlos E. Bueso‐Ramos, Blood	2007	460
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma Paul G. Richardson, Constantine Mitsiades, Kathleen Colson, Leukemia & lymphoma/Leukemia and lymphoma	2008	191
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma Michael Crump, Bertrand Coiffier, Eric D. Jacobsen, Annals of Oncology Hematological MalignancyLymphoid NeoplasiaOncologyPhase Ii TrialMedicine	2008	178
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer Johan Vansteenkiste, Eric Van Cutsem, Herlinde Dumez, Investigational New Drugs MedicineRefractory BreastBronchial NeoplasmBreast CancerCancer Treatment	2008	172
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer George R. Blumenschein, Merrill S. Kies, Vassiliki A. Papadimitrakopoulou, Investigational New Drugs Neck CancerPhase Ii TrialSuberoylanilide Hydroxamic AcidMedicinePharmacology	2007	166
Nuclear Factor-κB is an Important Modulator of the Altered Gene Expression Profile and Malignant Phenotype in Squamous Cell Carcinoma Amy Loercher, Justin L. Ricker, April Howard, Cancer Research	2004	166

Page 1